Neutralizing Monoclonal Antibodies against the Gn and the Gc of the Andes Virus Glycoprotein Spike Complex Protect from Virus Challenge in a Preclinical Hamster Model

2020/03/24 by James Duehr, Meagan McMahon, Brandi N. Williamson +8 · 1 voice · 25 citations
Medicine · #Viral Infections and Vectors #Mosquito-borne diseases and control #Viral Infections and Outbreaks Research

paper · doi:10.1128/mbio.00028-20

Abstract

Infections with New World hantaviruses are associated with high case fatality rates, and no specific vaccine or treatment options exist. Furthermore, the biology of the hantaviral GnGc complex, its antigenicity, and its fusion machinery are poorly understood. Protective monoclonal antibodies against GnGc have the potential to be developed into therapeutics against hantaviral disease and are also great tools to elucidate the biology of the glycoprotein complex.

Cited by

• Humoral Immunity to Hantavirus Infection. [europepmc]
• Biodefense Implications of New-World Hantaviruses. [europepmc]
• Molecular rationale for antibody-mediated targeting of the hantavirus fusion glycoprotein. [europepmc]
• Broad and potently neutralizing monoclonal antibodies isolated from human survivors of New World hantavirus infection. [europepmc]
• Protective neutralizing antibodies from human survivors of Crimean-Congo hemorrhagic fever. [europepmc]
• Structural Basis for a Neutralizing Antibody Response Elicited by a Recombinant Hantaan Virus Gn Immunogen. [europepmc]
• Murine Monoclonal Antibodies against the Receptor Binding Domain of SARS-CoV-2 Neutralize Authentic Wild-Type SARS-CoV-2 as Well as B.1.1.7 and B.1.351 Viruses and Protect In Vivo in a Mouse Model in a Neutralization-Dependent Manner. [europepmc]
• Polyclonal alpaca antibodies protect against hantavirus pulmonary syndrome in a lethal Syrian hamster model. [europepmc]
• Therapeutic Efficacy of Human Monoclonal Antibodies against Andes Virus Infection in Syrian Hamsters. [europepmc]
• The Input of Structural Vaccinology in the Search for Vaccines against Bunyaviruses. [europepmc]
• Building a better antibody through the Fc: advances and challenges in harnessing antibody Fc effector functions for antiviral protection. [europepmc]
• Human antibody recognizing a quaternary epitope in the Puumala virus glycoprotein provides broad protection against orthohantaviruses. [europepmc]
• BCG-Based Vaccines Elicit Antigen-Specific Adaptive and Trained Immunity against SARS-CoV-2 and Andes orthohantavirus . [europepmc]
• Antigenic mapping and functional characterization of human New World hantavirus neutralizing antibodies. [europepmc]
• Andes Virus Genome Mutations That Are Likely Associated with Animal Model Attenuation and Human Person-to-Person Transmission. [europepmc]
• Structural and mechanistic basis of neutralization by a pan-hantavirus protective antibody. [europepmc]
• Mechanistic basis for potent neutralization of Sin Nombre hantavirus by a human monoclonal antibody. [europepmc]
• Hantavirus: an overview and advancements in therapeutic approaches for infection. [europepmc]
• Sin Nombre Virus and the Emergence of Other Hantaviruses: A Review of the Biology, Ecology, and Disease of a Zoonotic Pathogen. [europepmc]
• The Adaptive Immune Response against Bunyavirales . [europepmc]
• Preclinical evaluation of a fully human, quadrivalent-hantavirus polyclonal antibody derived from a non-human source. [europepmc]
• Discovery and characterization of potent broadly neutralizing antibodies from human survivors of severe fever with thrombocytopenia syndrome. [europepmc]
• Standardization, validation, and comparative evaluation of a convenient surrogate recombinant vesicular stomatitis virus plaque reduction test for quantification of Hantaan orthohantavirus (HTNV) neutralizing antibodies. [europepmc]
• Achievement and Challenges in Orthohantavirus Vaccines. [europepmc]
• Puumala orthohantavirus: prevalence, biology, disease, animal models and recent advances in therapeutics development and structural biology. [europepmc]

Discussions

• Interesting paper to revisit during the current #hantavirus outbreak. This study shows monoclonal antibodies against #Andes virus could protect in preclinical models — highlighting their potential r [bsky, 17 points, 1 comments]

Related

• High-resolution in situ structures of hantavirus glycoprotein tetramers
• Human antibody targeting Crimean-Congo hemorrhagic fever virus glycoprotein 38 protects mice against heterologous virus challenge
• Efficacy of Human Monoclonal Antibody Monotherapy Against Bundibugyo Virus Infection in Nonhuman Primates
• Neutralizing antibodies protect mice against Venezuelan equine encephalitis virus aerosol challenge
• Inhibition of the interaction between the SARS-CoV Spike protein and its cellular receptor by anti-histo-blood group antibodies